DataMeds AI says Corexa Pharmacy tops $1 million in monthly revenue

DataMeds AI said Corexa Pharmacy generated more than $1 million in preliminary, unaudited revenue in September 2026, up more than 66% from July. The company is pointing to retail growth, new Tollo Health products and new fulfillment channels as it pushes the pharmacy toward a broader patient-services model.

Why it matters: - Corexa Pharmacy crossing the $1 million monthly revenue mark signals faster growth inside a business line DataMeds AI wants to use as a distribution and patient-services hub. - The revenue jump comes as the company ties pharmacy operations to GLP-1 patients, Long COVID offerings, telehealth fulfillment and new adjunct products. - The result could help validate DataMeds AI’s wider strategy around pharmacy, artificial intelligence and health-technology integration.

What happened: - DataMeds AI said Corexa Pharmacy recorded preliminary, unaudited revenue of more than $1 million in September 2026. - The company said that was more than 66% higher than revenue reported for July 2026. - Gerald Commissiong, Interim Co-CEO of DataMeds AI and CEO of Tollo Health, said the growth followed the rebranding of Corexa Pharmacy in the first month of the third quarter of 2026. - Commissiong said the company is seeing growth from a larger retail customer base and the recent launch of Tollo Health proprietary dietary supplements and medical foods.

The details: - DataMeds AI said Corexa Pharmacy is beginning to see growth in both prescriptions filled and adjunct product sales. - The company said Corexa Pharmacy is being positioned as a dispensing and patient-experience brand for patients using GLP-1 receptor agonist FDA-approved prescription drugs and for the Long COVID community. - DataMeds AI said the Health Lives Here mobile application now offers Corexa Pharmacy as a fulfillment option for telehealth prescriptions. - The company said the Helomics Corporation acquisition could open demand for oncology-based medications and nutritional support products. - DataMeds AI said it is upgrading Corexa Pharmacy’s physical location to serve as the flagship model for its Health Lives Here initiative with NFL Alumni Health. - Corexa Pharmacy is intended to be a model for other pharmacies in Corexa Health’s more than 6,500 independent pharmacy network. - The network includes physical retail locations that are seeking to expand into patient service centers for GLP-1 receptor agonist consumers and Long COVID patients. - DataMeds AI said Corexa Health distributes Tollo Health products under a wholesale arrangement. - Tollo Health commercializes proprietary medical foods and dietary supplements and, through TolloBio, is developing biopharmaceutical candidates. - DataMeds AI said its platforms include EinsteinRx™ and PharmacyChain™.

Between the lines: - The revenue update suggests Corexa Pharmacy is being used as more than a dispensing operation; it is becoming a channel for higher-margin adjunct products and broader service offerings. - The emphasis on telehealth, wholesale distribution and a large independent-pharmacy network points to a scale strategy rather than a single-location retail play. - The company’s repeated focus on GLP-1 and Long COVID markets shows where it expects demand to concentrate.

What's next: - DataMeds AI expects Corexa Pharmacy growth to continue as the retail base expands and adjunct product sales increase. - The company expects the Health Lives Here mobile application and the upgraded pharmacy location to support future growth. - DataMeds AI also pointed to potential future demand from the Helomics acquisition and the broader Health Lives Here and NFL Alumni Health rollout. - The company’s forward-looking statements also referenced potential continued growth in Corexa revenue, the success of its platform expansion and its proposed transaction involving DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors.

The bottom line: - Corexa Pharmacy’s September revenue milestone gives DataMeds AI a concrete growth metric as it tries to turn pharmacy operations, product distribution and digital health tools into a larger healthcare platform.